Possible vasculoprotective role of linagliptin against sodium arsenite-induced vascular endothelial dysfunction

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 389, Issue 2, 2016, Pages 167-175

  Jyoti, Uma ^a   Kansal, Sunil Kumar ^a   Kumar, Puneet ^b   Goyal, Sandeep ^a  

^a BABA FARID UNIVERSITY OF HEALTH SCIENCES   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

l arginine; L NAME; Linagliptin; Oxidative stress; Sodium arsenite; Vascular endothelial dysfunction

Indexed keywords

ARGININE; ARSENITE SODIUM; ATORVASTATIN; BIOLOGICAL MARKER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE; LINAGLIPTIN; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRITE; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; ARSENOUS ACID DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NOS3 PROTEIN, RAT; SODIUM DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HISTOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; BLOOD; CELL PROTECTION; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; AORTA, THORACIC; ARSENITES; CYTOPROTECTION; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FEMALE; GLUTATHIONE; LINAGLIPTIN; MALE; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; OXIDATIVE STRESS; PHOSPHORYLATION; RATS, WISTAR; SODIUM COMPOUNDS; SUPEROXIDES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 84954477863     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-015-1184-4     Document Type: Article

References (42)

1. Argos M, Kalra T, Rathouz PJ, Chen Y, Pierce B, Parvez F, Islam T, Ahmed A, Rakibuzzaman M, Hasan R, Sarwar G, Slavkovich V, Geen AV, Graziano J, Ahsan H (2010) Arsenic exposure from drinking water and all cause and chronic disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet 376:252-258
2. Aroor AR, Sowers JR, Jia G, De Marco VG (2014) Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol 307(4):H477-H492
3. Balakumar P, Kaur J (2009) Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc Toxicol 9:169-176
4. Bohm M (2007) Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? Am J Cardiol 100:38-44
5. Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23:168-175
6. Bunderson M, Coffin JD, Beall HD (2002) Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role of atherosclerosis. Toxicol Appl Pharmacol 184:11-18
7. Chuaiphichai S, McNeill E, Douglas G, Crabtree MJ, Bendall JK, Hale AB, Alp NJ, Channon KM (2014) Cell-autonomous role of endothelial GTP cyclohydrolase 1 and tetrahydrobiopterin in blood pressure regulation. Hypertens 64:530-540
8. Desjardins F, Balligand JL (2006) Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg 61:326-334
9. Flora SJS, Flora GJ, Saxena G (2009) Arsenicals: toxicity, their use as chemical warfare agents and possible remedial measures. In: Gupta RC (ed) Handbook of the toxicology of chemical warfare agents. Academic, San Diego, pp 109-133
10. Giansante C, Fiotti N (2006) Insights into human hypertension: the role of endothelial dysfunction. J Human Hypertens 20:725-726
11. Goyal S, Kumar S, Bijjem KV, Singh M (2010) Role of glucagon-like peptide in vascular endothelial dysfunction. Indian J Exp Biol 48:61-69
12. Han L, Yu Y, Sun X, Wang B (2012) Exendin-4 directly improves endothelial dysfunction in isolated aorta from obese rat through cAMP or AMPK-eNOS pathway. Diabetes Res Clin Pract 97:453-460
13. Hwang J, Kleimbenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM (2005) Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288:C899-C905
14. Ignarro LJ, Byrns RE, Buga GM, Wood KS, Chaudhuri G (1988) Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J Pharmacol Exp Ther 244:181-189
15. Kesavan M, Sarath TS, Kannan K, Suresh S, Gupta P, Vijay Akaran K, Sankar P, Kurade PN, Mishra SK, Sarkar SN (2014) Atorvastatin restores arsenic induced vascular dysfunction in rats: modulation of nitric oxide signaling and inflammatory mediators. Toxicol Appl Pharmacol 280:107-116
16. Kohn AD, Summer SA, Bimbaum MJ, Roth RA (1996) Expression of constituvely active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271:31372
17. Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta D, Kusaka H, Ma M, Nakagawa T, Lin B, Kim-Mitsuyama S (2014) DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol 13:157
18. 6, and folic acid on parameters of endothelial dysfunction and microcirculation in the placenta in modelling of L-NAME induced NO deficiency. Bull Exp Biol Med 152:77-79
19. Kroller-Schon S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, Sudowe S, Scholz A, Daub S, Karbach S, Kossmann S, Gori W, Schulz P, Grabbe E, Klein S, Munzel T, Daiber A (2012) Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 96(1):140-149
20. Liang C, Ren Y, Tan H, He Z, Jiang Q, Wu J, Zhen Y, Fan M, Wu Z (2009) Rosiglitazone via up-regulation of Akt/eNOS pathways attenuates dysfunction if endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 158:1865-1873
21. Ma F, Liu L, Xiong X (2003) Protective effects of pravastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol Sin 24:1027-1032
22. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H (2013) Dipeptidylpeptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77(5):1337-1344
23. Mittra S, Singh M (1998) Possible mechanism of captopril induced endothelium-dependent relaxation in isolated rabbit aorta. Mol Cell Biochem 183:63-67
24. Moya M, Campana V, Gavotto A, Spitale L, Simes J, Palma J (1999) Histopathological lesions in aorta from rats with hiperfrinogenemia published by 2nd virtual congress of cardiology
25. Nakashima S, Matsui T, Takeuchi H, Yamagishi S (2014) Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products receptor axis. Horm Metab Res 46:717-721
26. Neumiller JJ, Stephen M (2012) Review of linagliptin or the treatment of type 2 diabetes mellitus. Clin Ther 34:993-1005
27. Pieper GM (1997) Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobioprotein. J Cardiovasc Pharmacol 29:8-15
28. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF (2003) The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66(8):1499-1503
29. Pratico D (2005) Antioxidants and endothelium protection. Atherosclerosis 181:215-224
30. Salheen SM, Panchapakesan U, Pollock CA, Woodman OL (2015) The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol Res 94:26-33
31. Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M (2015) Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice, Vasc Pharmacol article in press
32. Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS (2002) Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem 306:79-82
33. Scheen AJ (2013) Cardiovascular effects of gliptins. Nat Res Cardiol 10:73-84
34. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katasichti P, Stefanadis C, Mavrikakis M (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56:1985-1993
35. Stea I, Bianchi F, Cori L, Sicari R (2014) Cardiovascular effect of arsenic: clinical and epidemiological finding. Environ Sci Pollut Res 21:244-251
36. Takai S, Sakonjo H, Jin D (2014) Significance of vascular dipeptidyl peptidase-IV inhibition on vascular protection in zuckar diabetic fatty rats. Pharmacol Sci 125:386-393
37. Takayama M, Yao K, Wada M (2009) The dihydropyridine calcium channel blocker benidipine prevents lysophosphatidylcholine induced endothelial dysfunction in rat aorta. J Bio Med Sci 16:57
38. Terasaki M, Nagashima M, Nohtomi K, Kohashi K, Tomoyasu M, Sinmura K, Nogi Y, Katayama Y, Sato K, Itoh F, Watanabe T, Hirano T (2013) Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 8(8):e70933
39. Wang HD, Pagano PJ, Du Y (1998) Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 82:810-818
40. Widenmaier SB, Sampaio AV, Underhill TM, McIntosh CHS (2009) Noncanonical activation of Akt/protein kinase B in β-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem 284:10764
41. Yamagishi S, Ishibashi Y, Ojima A, Sugiura T, Matsui T (2014) Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol 176:550-552
42. Yang Z, Ming XF (2006) Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 4:53-56